This management seem to be experienced operators and history shows they know how to get FDA approval efficiently on a short cycle.....they know how the system works, but they know when they are on a good product and how to leverage its use commercially, to maximise downstream ongoing revenue.
I am a happy holder and may even look to top up.
DYOR
Ann: Botanix Enrols First Patients in Dermatitis Study, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.010(6.25%) |
Mkt cap ! $333.3M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 18.0¢ | 16.0¢ | $3.403M | 19.98M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11400 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 1048293 | 11 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| BOT (ASX) Chart |